文献速递肺结节与肺癌肺栓塞与肺血管病

肺癌筛查队列中心血管风险评估的横断面研究

Evaluation of cardiovascular risk in a lung cancer screening cohort.
PubMed 文献 · Thorax · 2019-09-26

本研究在肺癌筛查项目(LSUT)中纳入60–75岁现吸烟者与既往吸烟者,行心血管疾病风险评估并用QRISK2估算10年CVD风险,同时行非门控非增强低剂量CT检测冠状动脉钙化(CAC)。最终分析680人,421人(61.9%)存在CAC,668人(98%)QRISK2≥10%,QRISK2与CAC分级呈正相关,符合他汀一级预防者中56.8%未报告他汀使用史。

要点

  • 肺癌筛查参与者中CAC普遍存在,可同步评估冠脉钙化。
  • QRISK2≥10%者占98%,但多数符合他汀一级预防者未用他汀。
  • 无论LDCT是否检出CAC,均应开展CVD风险评估。

核心结论

  • 在肺癌筛查队列中开展CVD风险评估可行,且不应依赖LDCT是否检出CAC。
  • QRISK2与CAC分级呈正相关,但CAC能否提升一级预防依从性仍需进一步研究。

研究设计与样本

  • 横断面研究,依托Lung Screen Uptake Trial(LSUT)。
  • 邀请60–75岁现吸烟者与既往吸烟者参加「lung health check」。
  • 收集数据包括CVD风险评估,用QRISK2估算10年CVD风险。
  • 符合所需肺癌风险者接受非门控、非增强低剂量CT。
  • 共1005人入组,680人纳入最终分析。

主要发现

  • 421人(61.9%)存在CAC,其中49人(7.2%)为重度钙化。
  • 668人(98%)QRISK2≥10%。
  • QRISK2与CAC分级升高呈正相关:QRISK2=10%–20%的OR为4.29(CI 0.93–19.88),QRISK2≥20%的OR为12.29(CI 2.68–56.1)。
  • 符合他汀一级预防条件(QRISK2≥10%)者中,56.8%未报告他汀使用史。
  • 多因素分析中他汀使用与年龄、体重指数及高血压和糖尿病史相关。

关键数值与推荐

  • CAC存在定义为LDCT检出冠状动脉钙化,重度钙化49例(7.2%)。
  • 他汀一级预防条件采用QRISK2≥10%。
  • QRISK2=10%–20%对应CAC分级升高的OR为4.29(CI 0.93–19.88)。
  • QRISK2≥20%对应CAC分级升高的OR为12.29(CI 2.68–56.1)。

临床怎么用

  • 在肺癌筛查中同步进行CVD风险评估,不论LDCT是否检出CAC。
  • 对QRISK2≥10%者评估他汀一级预防的使用情况。
  • 将CAC信息作为CVD风险沟通与随访的辅助内容。

局限性

  • 为横断面研究,无法确定CAC对一级预防依从性的因果作用。
  • 作者指出需进一步研究CAC能否提升一级预防策略的接受与依从。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lung cancer screening (LCS) by low-dose computed tomography (LDCT) offers an opportunity to impact both lung cancer and coronary heart disease mortality through detection of coronary artery calcification (CAC). Here, we explore the value of CAC and cardiovascular disease (CVD) risk assessment in LCS participants in the Lung Screen Uptake Trial (LSUT). METHODS: In this cross-sectional study, current and ex-smokers aged 60-75 were invited to a 'lung health check'. Data collection included a CVD risk assessment enabling estimation of 10 year CVD risk using the QRISK2 score. Participants meeting the required lung cancer risk underwent an ungated, non-contrast LDCT. Descriptive data, bivariate associations and a multivariate analysis of predictors of statin use are presented. RESULTS: Of 1005 individuals enrolled, 680 were included in the final analysis. 421 (61.9%) had CAC present and in 49 (7.2%), this was heavy. 668 (98%) of participants had a QRISK2≥10% and QRISK2 was positively associated with increasing CAC grade (OR 4.29 (CI 0.93 to 19.88) for QRISK2=10%-20% and 12.29 (CI 2.68 to 56.1) for QRISK2≥20% respectively). Of those who qualified for statin primary prevention (QRISK2≥10%), 56.8% did not report a history of statin use. In the multivariate analysis statin use was associated with age, body mass index and history of hypertension and diabetes. CONCLUSIONS: LCS offers an important opportunity for instituting CVD risk assessment in all LCS participants irrespective of the presence of LDCT-detected CAC. Further studies are needed to determine whether CAC could enhance uptake and adherence to primary preventative strategies.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Ruparel M, Quaife SL, Dickson JL, et al. Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax. 2019. PMID: 31558626. doi:10.1136/thoraxjnl-2018-212812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。